- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lorad scores deal with U.S. Surgical
Mammography vendor Lorad of Danbury, CT, has signed an exclusivemultiyear agreement with breast biopsy instrument supplier U.S.Surgical that could be worth up to $10 million to Lorad in thefirst year of the contract. Under the terms of the deal,
Mammography vendor Lorad of Danbury, CT, has signed an exclusivemultiyear agreement with breast biopsy instrument supplier U.S.Surgical that could be worth up to $10 million to Lorad in thefirst year of the contract. Under the terms of the deal, Loradwill supply stereotactic equipment such as its StereoGuide coreneedle biopsy system to U.S. Surgical for use with that company'sAdvanced Breast Biopsy Instrument (ABBI) system. ABBI employsa one-step procedure to both place a wire marker in the breastand remove a tissue specimen for biopsy.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
